Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
Identifieur interne : 002309 ( Main/Merge ); précédent : 002308; suivant : 002310Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
Auteurs : Hiroshi Nagayama [Japon] ; Masayuki Ueda [Japon] ; Mineo Yamazaki [Japon] ; Yasuhiro Nishiyama [Japon] ; Makoto Hamamoto [Japon] ; Yasuo Katayama [Japon]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-08-15.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), Aged, Female, Heart (radionuclide imaging), Humans, Iodine Radioisotopes (diagnostic use), Longitudinal Studies, MIBG, Male, Middle Aged, Multiple System Atrophy (diagnosis), Multiple System Atrophy (radionuclide imaging), Myocardial Perfusion Imaging (methods), Radiopharmaceuticals (diagnostic use), Retrospective Studies, Statistics, Nonparametric, Time Factors, multiple system atrophy, myocardial scintigraphy.
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Iodine Radioisotopes, Radiopharmaceuticals.
- diagnosis : Multiple System Atrophy.
- methods : Myocardial Perfusion Imaging.
- radionuclide imaging : Heart, Multiple System Atrophy.
- Aged, Female, Humans, Longitudinal Studies, Male, Middle Aged, Retrospective Studies, Statistics, Nonparametric, Time Factors.
Abstract
[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23338
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001321
- to stream Istex, to step Curation: 001321
- to stream Istex, to step Checkpoint: 000B52
- to stream PubMed, to step Corpus: 001708
- to stream PubMed, to step Curation: 001708
- to stream PubMed, to step Checkpoint: 001A64
- to stream Ncbi, to step Merge: 002D09
- to stream Ncbi, to step Curation: 002D09
- to stream Ncbi, to step Checkpoint: 002D09
Links to Exploration step
ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23338</idno><idno type="url">https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001321</idno><idno type="wicri:Area/Istex/Curation">001321</idno><idno type="wicri:Area/Istex/Checkpoint">000B52</idno><idno type="wicri:doubleKey">0885-3185:2010:Nagayama H:abnormal:cardiac:i</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20645402</idno><idno type="wicri:Area/PubMed/Corpus">001708</idno><idno type="wicri:Area/PubMed/Curation">001708</idno><idno type="wicri:Area/PubMed/Checkpoint">001A64</idno><idno type="wicri:Area/Ncbi/Merge">002D09</idno><idno type="wicri:Area/Ncbi/Curation">002D09</idno><idno type="wicri:Area/Ncbi/Checkpoint">002D09</idno><idno type="wicri:Area/Main/Merge">002309</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1744">1744</biblScope><biblScope unit="page" to="1747">1747</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><idno type="DOI">10.1002/mds.23338</idno><idno type="ArticleID">MDS23338</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Aged</term><term>Female</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Longitudinal Studies</term><term>MIBG</term><term>Male</term><term>Middle Aged</term><term>Multiple System Atrophy (diagnosis)</term><term>Multiple System Atrophy (radionuclide imaging)</term><term>Myocardial Perfusion Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term><term>multiple system atrophy</term><term>myocardial scintigraphy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Iodine Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Myocardial Perfusion Imaging</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Heart</term><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.23338"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23338</idno><idno type="url">https://api.istex.fr/document/0E7C00AA65D43F1FDA7276F00F617A72913D7337/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001321</idno><idno type="wicri:Area/Istex/Curation">001321</idno><idno type="wicri:Area/Istex/Checkpoint">000B52</idno><idno type="wicri:doubleKey">0885-3185:2010:Nagayama H:abnormal:cardiac:i</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1744">1744</biblScope><biblScope unit="page" to="1747">1747</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0E7C00AA65D43F1FDA7276F00F617A72913D7337</idno><idno type="DOI">10.1002/mds.23338</idno><idno type="ArticleID">MDS23338</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MIBG</term><term>multiple system atrophy</term><term>myocardial scintigraphy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[123I]‐Meta‐iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow‐up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. © 2010 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="3"><nlm:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan. nagayama@nms.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23338</idno><idno type="RBID">pubmed:20645402</idno><idno type="pmid">20645402</idno><idno type="wicri:Area/PubMed/Corpus">001708</idno><idno type="wicri:Area/PubMed/Curation">001708</idno><idno type="wicri:Area/PubMed/Checkpoint">001A64</idno><idno type="wicri:Area/Ncbi/Merge">002D09</idno><idno type="wicri:Area/Ncbi/Curation">002D09</idno><idno type="wicri:Area/Ncbi/Checkpoint">002D09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="3"><nlm:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan. nagayama@nms.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Aged</term><term>Female</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Multiple System Atrophy (diagnosis)</term><term>Multiple System Atrophy (radionuclide imaging)</term><term>Myocardial Perfusion Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Iodine Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Myocardial Perfusion Imaging</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Heart</term><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[(123)I]-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow-up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002309 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002309 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:0E7C00AA65D43F1FDA7276F00F617A72913D7337
|texte= Abnormal cardiac [123I]‐meta‐iodobenzylguanidine uptake in multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |